Rescheduling Psilocybin as a Schedule IV Substance
This proposed bill would reschedule the pharmaceutical composition of crystalline polymorph psilocybin in drug products approved by the Food and Drug Administration from its current classification to a Schedule IV controlled substance. This change would affect manufacturers, distributors, prescribers, and users of this specific form of psilocybin. The exact effective date is not specified.
Psilocybin was previously classified under a different schedule of controlled substances, and this bill proposes to change its classification to Schedule IV.
This proposed bill would reschedule the pharmaceutical composition of crystalline polymorph psilocybin in drug products approved by the Food and Drug Administration from its current classification to a Schedule IV controlled substance. This change would affect manufacturers, distributors, prescribers, and users of this specific form of psilocybin. The exact effective date is not specified.